OpenURL Connection Search

Select item for more details and to access through your institution.

CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B‐CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 140, doi. 10.1002/hon.99_2629
By:
- Balasubramanian, S.;
- Wang, S.;
- Major, C.;
- Hodkinson, B.;
- Schaffer, M.;
- Sehn, L.H.;
- Johnson, P.;
- Zinzani, P.L.;
- Carey, J.;
- Liu, G.;
- Loefgren, C.;
- Shreeve, M.;
- Sun, S.;
- Zhuang, S.;
- Vermeulen, J.;
- Staudt, L.M.;
- Younes, A.;
- Wilson, W.
Publication type:
Article
ESTIMATION OF LONG‐TERM SURVIVAL WITH POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB FOR PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL).
Published in:
Hematological Oncology, 2019, v. 37, p. 257, doi. 10.1002/hon.66_2630
By:
- Sehn, L.H.;
- Flowers, C.;
- McMillan, A.;
- Morschhauser, F.;
- Salles, G.;
- Felizzi, F.;
- Launonen, A.;
- Qayum, N.;
- Thuresson, P.O.
Publication type:
Article
POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R‐CHP VERSUS R‐CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL.
Published in:
Hematological Oncology, 2019, v. 37, p. 68, doi. 10.1002/hon.36_2629
By:
- Tilly, H.;
- Flowers, C.;
- Friedberg, J.W.;
- Herbaux, C.;
- Morschhauser, F.;
- Sehn, L.H.;
- Sharman, J.;
- Trněný, M.;
- Lee, C.;
- Salles, G.
Publication type:
Article
RADIOMICS INCREASE THE PROGNOSTIC VALUE OF CLINICAL AND PET RISK FACTORS IN DLBCL: RESULTS FROM THE PHASE 3 GOYA STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 52, doi. 10.1002/hon.21_2629
By:
- Chauvie, S.;
- Dalmasso, F.;
- Pierce, L.;
- Vitolo, U.;
- Martelli, M.;
- Sehn, L.H.;
- Trněný, M.;
- Nielsen, T.;
- Sahin, D.;
- Lee, C.;
- Mattiello, F.;
- Berchialla, P.;
- Kinahan, P.E.;
- Kostakoglu, L.
Publication type:
Article
BASELINE TOTAL METABOLIC TUMOUR VOLUME IS HIGHLY PROGNOSTIC FOR REFRACTORINESS TO IMMUNOCHEMOTHERAPY IN DLBCL: AN ANALYSIS OF THE PHASE 3 GOYA TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 50, doi. 10.1002/hon.20_2629
By:
- Trněný, M.;
- Canales Ruiz, I.;
- Martelli, M.;
- Sehn, L.H.;
- Vitolo, U.;
- Brown, H.;
- Nielsen, T.;
- Sellam, G.;
- Kostakoglu, L.
Publication type:
Article
AN ONGOING PHASE 1/1B TRIAL INVESTIGATING NOVEL TREATMENT REGIMENS WITH MOSUNETUZUMAB IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 567, doi. 10.1002/hon.15_2632
By:
- Kim, W.S.;
- Assouline, S.;
- Bartlett, N.L.;
- Bosch, F.;
- Budde, L.E.;
- Cheah, C.;
- Gregory, G.P.;
- Hong, J.;
- Ku, M.;
- Marlton, P.;
- Matasar, M.;
- Nastoupil, L.;
- Panizo, C.;
- Sehn, L.H.;
- Tzachanis, D.;
- Chu, W.;
- Hernandez, M.G.;
- Kwan, A.;
- Li, C.C.;
- Sison, I.
Publication type:
Article
MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL).
Published in:
Hematological Oncology, 2019, v. 37, p. 310, doi. 10.1002/hon.119_2630
By:
- Sehn, L.H.;
- Assouline, S.;
- Bartlett, N.L.;
- Bosch, F.;
- Diefenbach, C.M.;
- Flinn, I.;
- Hong, J.Y.;
- Kim, W.S.;
- Matasar, M.;
- Nastoupil, L.;
- Schuster, S.J.;
- Shadman, M.;
- Yoon, S.S.;
- Bender, B.;
- Chu, W.;
- Hernandez, G.M.;
- Kwan, A.;
- McCall, B.;
- Sison, I.;
- Wang, C.
Publication type:
Article
OUTCOME OF PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA IN THE RITUXIMAB ERA: IMPACT OF A PET‐GUIDED APPROACH.
Published in:
Hematological Oncology, 2019, v. 37, p. 156, doi. 10.1002/hon.113_2629
By:
- Hayden, A.;
- Tonseth, P.;
- Villa, D.;
- Gerrie, A.S.;
- Scott, D.W.;
- Freeman, C.L.;
- Slack, G.W.;
- Parsons, C.;
- Pickles, T.;
- Wilson, D.;
- Connors, J.M.;
- Sehn, L.H.;
- Savage, K.J.
Publication type:
Article
CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B‐CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 140, doi. 10.1002/hon.99_2629
By:
- Balasubramanian, S.;
- Wang, S.;
- Major, C.;
- Hodkinson, B.;
- Schaffer, M.;
- Sehn, L.H.;
- Johnson, P.;
- Zinzani, P.L.;
- Carey, J.;
- Liu, G.;
- Loefgren, C.;
- Shreeve, M.;
- Sun, S.;
- Zhuang, S.;
- Vermeulen, J.;
- Staudt, L.M.;
- Younes, A.;
- Wilson, W.
Publication type:
Article
ESTIMATION OF LONG‐TERM SURVIVAL WITH POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB FOR PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL).
Published in:
Hematological Oncology, 2019, v. 37, p. 257, doi. 10.1002/hon.66_2630
By:
- Sehn, L.H.;
- Flowers, C.;
- McMillan, A.;
- Morschhauser, F.;
- Salles, G.;
- Felizzi, F.;
- Launonen, A.;
- Qayum, N.;
- Thuresson, P.O.
Publication type:
Article
POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R‐CHP VERSUS R‐CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL.
Published in:
Hematological Oncology, 2019, v. 37, p. 68, doi. 10.1002/hon.36_2629
By:
- Tilly, H.;
- Flowers, C.;
- Friedberg, J.W.;
- Herbaux, C.;
- Morschhauser, F.;
- Sehn, L.H.;
- Sharman, J.;
- Trněný, M.;
- Lee, C.;
- Salles, G.
Publication type:
Article
RADIOMICS INCREASE THE PROGNOSTIC VALUE OF CLINICAL AND PET RISK FACTORS IN DLBCL: RESULTS FROM THE PHASE 3 GOYA STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 52, doi. 10.1002/hon.21_2629
By:
- Chauvie, S.;
- Dalmasso, F.;
- Pierce, L.;
- Vitolo, U.;
- Martelli, M.;
- Sehn, L.H.;
- Trněný, M.;
- Nielsen, T.;
- Sahin, D.;
- Lee, C.;
- Mattiello, F.;
- Berchialla, P.;
- Kinahan, P.E.;
- Kostakoglu, L.
Publication type:
Article
BASELINE TOTAL METABOLIC TUMOUR VOLUME IS HIGHLY PROGNOSTIC FOR REFRACTORINESS TO IMMUNOCHEMOTHERAPY IN DLBCL: AN ANALYSIS OF THE PHASE 3 GOYA TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 50, doi. 10.1002/hon.20_2629
By:
- Trněný, M.;
- Canales Ruiz, I.;
- Martelli, M.;
- Sehn, L.H.;
- Vitolo, U.;
- Brown, H.;
- Nielsen, T.;
- Sellam, G.;
- Kostakoglu, L.
Publication type:
Article
AN ONGOING PHASE 1/1B TRIAL INVESTIGATING NOVEL TREATMENT REGIMENS WITH MOSUNETUZUMAB IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 567, doi. 10.1002/hon.15_2632
By:
- Kim, W.S.;
- Assouline, S.;
- Bartlett, N.L.;
- Bosch, F.;
- Budde, L.E.;
- Cheah, C.;
- Gregory, G.P.;
- Hong, J.;
- Ku, M.;
- Marlton, P.;
- Matasar, M.;
- Nastoupil, L.;
- Panizo, C.;
- Sehn, L.H.;
- Tzachanis, D.;
- Chu, W.;
- Hernandez, M.G.;
- Kwan, A.;
- Li, C.C.;
- Sison, I.
Publication type:
Article
MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL).
Published in:
Hematological Oncology, 2019, v. 37, p. 310, doi. 10.1002/hon.119_2630
By:
- Sehn, L.H.;
- Assouline, S.;
- Bartlett, N.L.;
- Bosch, F.;
- Diefenbach, C.M.;
- Flinn, I.;
- Hong, J.Y.;
- Kim, W.S.;
- Matasar, M.;
- Nastoupil, L.;
- Schuster, S.J.;
- Shadman, M.;
- Yoon, S.S.;
- Bender, B.;
- Chu, W.;
- Hernandez, G.M.;
- Kwan, A.;
- McCall, B.;
- Sison, I.;
- Wang, C.
Publication type:
Article
OUTCOME OF PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA IN THE RITUXIMAB ERA: IMPACT OF A PET‐GUIDED APPROACH.
Published in:
Hematological Oncology, 2019, v. 37, p. 156, doi. 10.1002/hon.113_2629
By:
- Hayden, A.;
- Tonseth, P.;
- Villa, D.;
- Gerrie, A.S.;
- Scott, D.W.;
- Freeman, C.L.;
- Slack, G.W.;
- Parsons, C.;
- Pickles, T.;
- Wilson, D.;
- Connors, J.M.;
- Sehn, L.H.;
- Savage, K.J.
Publication type:
Article
FOXP1 EXPRESSION IS INVERSELY CORRELATED WITH EZH2 MUTATION STATUS AND PREDICTS POOR FAILURE-FREE SURVIVAL IN FOLLICULAR LYMPHOMA TREATED WITH RITUXIMAB AND CHEMOTHERAPY.
Published in:
Hematological Oncology, 2017, v. 35, p. 42, doi. 10.1002/hon.2437_23
By:
- Mottok, A.;
- Jurinovic, V.;
- Farinha, P.;
- Rosenwald, A.;
- Ott, G.;
- Klapper, W.;
- Boesl, M.;
- Hiddemann, W.;
- Steidl, C.;
- Connors, J.M.;
- Sehn, L.H.;
- Gascoyne, R.D.;
- Hoster, E.;
- Weigert, O.;
- Kridel, R.
Publication type:
Article
CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY.
Published in:
Hematological Oncology, 2017, v. 35, p. 43, doi. 10.1002/hon.2437_25
By:
- Klanova, M.;
- Sehn, L.H.;
- Bence ‐ Bruckler, I.;
- Cavallo, F.;
- Jin, J.;
- Martelli, M.;
- Stewart, D.;
- Vitolo, U.;
- Zaja, F.;
- Zhang, Q.;
- Mattiello, F.;
- Oestergaard, M.Z.;
- Fingerle ‐ Rowson, G.R.;
- Nielsen, T.;
- Trneny, M.
Publication type:
Article
MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE.
Published in:
Hematological Oncology, 2017, v. 35, p. 216, doi. 10.1002/hon.2438_80
By:
- Pott, C.;
- Belada, D.;
- Danesi, N.;
- Fingerle ‐ Rowson, G.R.;
- Gribben, J.;
- Harbron, C.G.;
- Hoster, E.;
- Kahl, B.S.;
- Kehden, B.;
- Mundt, K.E.;
- Nicolas ‐ Virelizier, E.;
- Sehn, L.H.;
- Cheson, B.D.
Publication type:
Article
PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION IN UNTREATED DLBCL: RESULTS FROM THE PHASE III GOYA STUDY.
Published in:
Hematological Oncology, 2017, v. 35, p. 131, doi. 10.1002/hon.2437_121
By:
- Sehn, L.H.;
- Oestergaard, M.Z.;
- Trněný, M.;
- Bosi, A.;
- Egyed, M.;
- Illes, A.;
- Nakamae, H.;
- Opat, S.;
- Topp, M.;
- Zaja, F.;
- Fingerle ‐ Rowson, G.;
- Lei, G.;
- Nielsen, T.;
- Punnoose, E.A.;
- Rahman, M.;
- Ray, J.;
- Zhang, L.;
- Martelli, M.;
- Vitolo, U.
Publication type:
Article
POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FL OR DLBCL: UPDATED RESULTS OF A PHASE 1B/2 STUDY.
Published in:
Hematological Oncology, 2017, v. 35, p. 271, doi. 10.1002/hon.2438_144
By:
- Matasar, M.;
- Herrera, A.F.;
- Kamdar, M.;
- Mehta, A.;
- Assouline, S.;
- Fleury, I.;
- Kim, T.M.;
- Kim, W.S.;
- Bosch, F.;
- Radford, J.;
- Flowers, C.R.;
- Bu, L.;
- Hong, W.;
- Sehn, L.H.
Publication type:
Article
END OF TREATMENT PET-CT PREDICTS PROGRESSION-FREE SURVIVAL IN DLBCL AFTER FIRST-LINE TREATMENT: RESULTS FROM THE PHASE III GOYA STUDY.
Published in:
Hematological Oncology, 2017, v. 35, p. 184, doi. 10.1002/hon.2438_45
By:
- Kostakoglu, L.;
- Martelli, M.;
- Belada, D.;
- Carella, A.M.;
- Chua, N.;
- Gonzalez ‐ Barca, E.;
- Hong, X.;
- Pinto, A.;
- Sehn, L.H.;
- Shi, Y.;
- Tatsumi, Y.;
- Fingerle ‐ Rowson, G.;
- Mattiello, F.;
- Nielsen, T.;
- Sahin, D.;
- Vitolo, U.;
- Trněný, M.
Publication type:
Article

Found: 22